Loading quotes...
Forecast
The analysts' average price target is €282.31 (+39.76%). The median is €289.94 (+43.53%).
| Buy |
Â
24 |
| Hold |
Â
2 |
| Sell |
Â
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 344.9m | 118.23% |
| Gross profit | 312.61m | 146.93% |
| Net profit | 210.4m | 641.49% |
| EBITDA | 68.08m | 2,835.57% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €12.6bn |
Number of shares | 62.11m |
52-week high/low | €250.94 - €165.47 |
| Dividends | No |
Beta | 0.37 |
P/E ratio | 16.80 |
PEG ratio | 0.03 |
P/B ratio | 9.11 |
P/S ratio | 11.97 |
Company profile
| Name | Ascendis Pharma ADR |
| CEO | Jan Moller Mikkelsen |
| Employees | 1,189 |
